Glenmark, Natco get final US nod for anti-migraine drug

Rizatriptan Benzoate orally disintegrating tablets are a generic version of Merck's Maxalt MLT Tablets.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Travelcafe
moneycontrol.com

Home » News » Business

Jul 27, 2013, 01.22 PM | Source: Moneycontrol.com

Glenmark, Natco get final US nod for anti-migraine drug

Rizatriptan Benzoate orally disintegrating tablets are a generic version of Merck's Maxalt MLT Tablets.

Like this story, share it with millions of investors on M3

Glenmark, Natco get final US nod for anti-migraine drug

Rizatriptan Benzoate orally disintegrating tablets are a generic version of Merck's Maxalt MLT Tablets.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Glenmark Pharma 's US generics subsidiary and another generics drugs maker Natco Pharma have received final approval from US Food and Drug Administration for Rizatriptan Benzoate orally disintegrating tablets, used to treat migraine headaches.

Both the companies have approval to sell the tablets in 5mg and 10mg strengths.

Rizatriptan ODT is a generic version of Merck's Maxalt MLT tablets and Glenmark said it will start shipping its tablets immediately.

Natco said it has already started shipping the product launched by its marketing partner Breckenridge Pharmaceuticals.

Rizatriptan ODT had sales of USD 263 million for the year ended March 2013, Glenmark said, citing IMS Health data.

Glenmark now has 87 products authorized for distribution in the US market and 53 ANDAs (abbreviated new drug application) are pending approval with the drug regulator.

Glenmark shares ended up about 1 percent at Rs 575.35 on NSE on Tuesday. Natco ended up 1.5 percent at Rs 454.65.

Also Read: RBI names 26 applicants for new banking licence

Nachiket Kelkar
nachiket.kelkar@network18online.com

Glenmark stock price

On May 05, 2016, Glenmark Pharma closed at Rs 815.65, down Rs 4.5, or 0.55 percent. The 52-week high of the share was Rs 1261.95 and the 52-week low was Rs 671.50.


The company's trailing 12-month (TTM) EPS was at Rs 57.81 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 14.11. The latest book value of the company is Rs 175.54 per share. At current value, the price-to-book value of the company is 4.65.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Glenmark, Natco get final US nod for anti-migraine drug

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login